Evaluation of PRDM10 gene rearrangement by immunohistochemistry and molecular methods in unclassifiable undifferentiated soft tissue tumors.

IF 1.2 4区医学 Q3 PATHOLOGY

Medical Molecular Morphology Pub Date : 2025-06-25 DOI:10.1007/s00795-025-00442-2

Merve Aksin, Kivilcim Eren Ates, Akif Mirioglu, Tugba Toyran, Gulfiliz Gonlusen

{"title":"Evaluation of PRDM10 gene rearrangement by immunohistochemistry and molecular methods in unclassifiable undifferentiated soft tissue tumors.","authors":"Merve Aksin, Kivilcim Eren Ates, Akif Mirioglu, Tugba Toyran, Gulfiliz Gonlusen","doi":"10.1007/s00795-025-00442-2","DOIUrl":null,"url":null,"abstract":"<p><p>Soft tissue sarcomas are heterogenous groups of tumors that show variable morphology as well as clinical behavior. Morphological features do not always directly reflect clinical behavior. Certain mesenchymal tumors exhibit an indolent clinical course. Among them are superficial CD34-positive fibroblastic tumors characterized by PRDM10 fusion. In our study, we aimed to detect PRDM10 gene rearrangement in superficial CD34-positive fibroblastic tumors and other pleomorphic sarcomas included in its differential diagnosis by immunohistochemistry and Fluorescence in situ hybridization. Totally, 33 cases were enrolled into this study. The results showed that two cases diagnosed as superficial CD34-positive fibroblastic tumor and two cases diagnosed as undifferentiated pleomorphic sarcoma have PRDM10 gene rearrangement. Immunohistochemically, not all rearranged tumors showed PRDM10 staining that suggests a low sensitivity of PRDM10 antibody. In conclusion, we suggested that PRDM10 gene rearrangement is not limited to superficial CD34-positive fibroblastic tumors; undifferentiated pleomorphic sarcomas may exhibit this molecular alteration and immunohistochemistry has lower sensitivity than fluorescence in situ hybridization.</p>","PeriodicalId":18338,"journal":{"name":"Medical Molecular Morphology","volume":" ","pages":""},"PeriodicalIF":1.2000,"publicationDate":"2025-06-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Medical Molecular Morphology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1007/s00795-025-00442-2","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"PATHOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Soft tissue sarcomas are heterogenous groups of tumors that show variable morphology as well as clinical behavior. Morphological features do not always directly reflect clinical behavior. Certain mesenchymal tumors exhibit an indolent clinical course. Among them are superficial CD34-positive fibroblastic tumors characterized by PRDM10 fusion. In our study, we aimed to detect PRDM10 gene rearrangement in superficial CD34-positive fibroblastic tumors and other pleomorphic sarcomas included in its differential diagnosis by immunohistochemistry and Fluorescence in situ hybridization. Totally, 33 cases were enrolled into this study. The results showed that two cases diagnosed as superficial CD34-positive fibroblastic tumor and two cases diagnosed as undifferentiated pleomorphic sarcoma have PRDM10 gene rearrangement. Immunohistochemically, not all rearranged tumors showed PRDM10 staining that suggests a low sensitivity of PRDM10 antibody. In conclusion, we suggested that PRDM10 gene rearrangement is not limited to superficial CD34-positive fibroblastic tumors; undifferentiated pleomorphic sarcomas may exhibit this molecular alteration and immunohistochemistry has lower sensitivity than fluorescence in situ hybridization.

查看原文本刊更多论文

免疫组织化学和分子方法评价PRDM10基因重排在无法分类的未分化软组织肿瘤中的作用。

软组织肉瘤是一种异质性的肿瘤，表现出不同的形态和临床行为。形态学特征并不总是直接反映临床行为。某些间充质肿瘤表现为惰性临床过程。其中以PRDM10融合为特征的浅表cd34阳性成纤维细胞肿瘤。在我们的研究中，我们旨在通过免疫组织化学和荧光原位杂交检测PRDM10基因重排在浅表cd34阳性的纤维母细胞肿瘤和其他多形性肉瘤的鉴别诊断。本研究共纳入33例病例。结果显示，2例浅表cd34阳性纤维母细胞瘤和2例未分化多形性肉瘤均存在PRDM10基因重排。免疫组化结果显示，并非所有重排肿瘤均显示PRDM10染色，提示PRDM10抗体敏感性较低。总之，我们认为PRDM10基因重排并不局限于表面cd34阳性的纤维母细胞肿瘤；未分化的多形性肉瘤可能表现出这种分子改变，免疫组织化学的敏感性低于荧光原位杂交。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Medical Molecular Morphology 医学-病理学

CiteScore

2.90

自引率

5.60%

发文量

审稿时长

>12 weeks

期刊介绍： Medical Molecular Morphology is an international forum for researchers in both basic and clinical medicine to present and discuss new research on the structural mechanisms and the processes of health and disease at the molecular level. The structures of molecules, organelles, cells, tissues, and organs determine their normal function. Disease is thus best understood in terms of structural changes in these different levels of biological organization, especially in molecules and molecular interactions as well as the cellular localization of chemical components. Medical Molecular Morphology welcomes articles on basic or clinical research in the fields of cell biology, molecular biology, and medical, veterinary, and dental sciences using techniques for structural research such as electron microscopy, confocal laser scanning microscopy, enzyme histochemistry, immunohistochemistry, radioautography, X-ray microanalysis, and in situ hybridization. Manuscripts submitted for publication must contain a statement to the effect that all human studies have been reviewed by the appropriate ethics committee and have therefore been performed in accordance with the ethical standards laid down in an appropriate version of the 1964 Declaration of Helsinki. It should also be stated clearly in the text that all persons gave their informed consent prior to their inclusion in the study. Details that might disclose the identity of the subjects under study should be omitted.